453 related articles for article (PubMed ID: 34855339)
1. Liver Disease: Nonalcoholic Fatty Liver Disease.
Cooper J; Baumgartner K; Smith A; St Louis J
FP Essent; 2021 Dec; 511():29-35. PubMed ID: 34855339
[TBL] [Abstract][Full Text] [Related]
2. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT; Noureddin M; Lim JK
Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
4. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
[TBL] [Abstract][Full Text] [Related]
5. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
Westfall E; Jeske R; Bader AR
Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890
[TBL] [Abstract][Full Text] [Related]
7. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease: a systematic review.
Rinella ME
JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
11. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
Belfort-DeAguiar R; Lomonaco R; Cusi K
J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
13. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
Cusi K; Isaacs S; Barb D; Basu R; Caprio S; Garvey WT; Kashyap S; Mechanick JI; Mouzaki M; Nadolsky K; Rinella ME; Vos MB; Younossi Z
Endocr Pract; 2022 May; 28(5):528-562. PubMed ID: 35569886
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
[TBL] [Abstract][Full Text] [Related]
15. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
17. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
18. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
19. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
Budd J; Cusi K
Am J Med; 2020 May; 133(5):536-543. PubMed ID: 32017891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
